Member Info for 2cvguy

Plenty of comment on the MHRA tardiness, but we're also waiting on the EMA. Hard to believe they are also so slow.

From the BBC . .

There are nearly 7,750 cases of ovarian cancer in the UK each year.

Up to 400 patients a year in England could benefit from the new treatment.

Allowing for the UK/England distinction, that's just 5 to maybe 7 percent of cases being treated with the drug. I assume this is down to suitability rather than financial constraint.

IIRC, Phil intimated that once the FDA approval came through, the MHRA and EMA approvals were almost a box ticking exercise. If that's right then he will be just as surprised and disappointed as we are at how long it is taking.

Hello ITT.

I've been diluted so much over the years that my holding is meagre now, but FWIW, count me in. At the very least I'd like to make things very uncomfortable the JC and HP.

Likely to have a meltdown if you tried it.

Loved the knowing smiles from Lindy and Phil in the Q&A when Nermeen was answering about fast-track, breakthrough drug, designation.

A big man in all respects. Made me very welcome at the first AGM I attended. It's a testament to him that his memory lives on on this board.

RIP C7.

This should work

https://is.gd/xVvzsj

You're an inspiration and the best example for us, C7. Keep punching !

It's all in the Investors section of the Scancell website.

https://scancell.co.uk/share-info/

Worth reading the Panmure analysis from the link in the sidebar on the video page which is very positive short and medium term.

"Funding requirements for large-scale global trials could prompt Scancell to seek additional partnerships or financing. However, L’Hullier’s leadership is expected to sharpen the company’s focus on business development and strategic alliances, complementing the scientific expertise of Durrant.

The growing awareness of the potential in the cancer vaccine field is translating to a rise in the profile of Scancell,” the investment bank said. “We believe positive data has the potential to trigger a re-rating.”

https://www.proactiveinvestors.co.uk/companies/news/1060871/scancell-s-new-ceo-takes-the-helm-of-a-cancer-immunotherapy-specialist-in-rude-health-1060871.html

Very nice indeed. Kind of hypnotic and makes you want to try all the menu links to see what the other pages are like. Might excite some interest.

The good doctor was educated at Waimea College, so looks like he was raised in the NZ town that was my home for a few years - it just feels like the stars are perfectly aligning for me personally !

It should be acknowledged what a great job Lindy has done as CEO, overseeing enormous progress.

"deliver" is the most significant word for me.

Think you've hit the nail on the head with your 13:28, ITT.

Interesting observation on the Nasdaq/CLN issue. However (and I may be wide of the mark here) if the CLN's can now be redeemed at any time rather than only on the original redemption date, then if a Nasdaq listing were to happen then Redmile would be able to convert without any time restriction, so there is no need for any clause about Nasdaq or an offer ? Am I missing something?

"H2 normally starts July 1st".

I think we know someone who could argue that it doesn't.

Https://www.bbc.co.uk/news/health-68897731

Can't say I was aware of this trial before, and I note it is a Phase 3 trial so earlier phases were apparently more under the radar (for me anyway).

I see some positives from this story:

- the combination with Pembro and Keytruda is validated

- results from this trial (49% improvement) will provide a comparison to SCIB1

- this is a personalised (expensive) treatment.

Hopefully we'll get this kind of front page coverage one day.

"how can price sensitive data be withheld from Shareholders until the opportunity arises such as AACR or ASCO, where 'previously unpublished data' is a requirement"

My guess - and it is only a guess - is that "published" means in a professional medical paper, rather than an RNS.

While you are factually correct, Ruck, IMO there is no reason the RNS cannot be both regulatory info and a marketing opportunity. If it was strictly regulatory compliance it would not have been relevant to use the phrase "exceptional results".